CMSO

Beyond price tags: What really drives consumer choices in fashion and footwear? Market Force study looks at top retail brands to uncover where consumers are spending and why

Retrieved on: 
Thursday, March 21, 2024
Old Navy, Kohl's, Fabletics, Motivation, Growth, Ross Stores, Nike, CMSO, Risk, H&M, Research, Clothing, Club Monaco, Macy's, Walmart, TJ Maxx, Dillards, Sport, Burlington (department store), Retail

Almost 5,500 (N = 5,462) consumers provided feedback about their experiences across popular department stores and specialty retail brands, providing specific feedback on both clothing and footwear retailers.

Key Points: 
  • Almost 5,500 (N = 5,462) consumers provided feedback about their experiences across popular department stores and specialty retail brands, providing specific feedback on both clothing and footwear retailers.
  • Consumers rated the top department store brands, clearly indicating preference for those they felt were value leaders.
  • The top department store brands in order were: Kohls, TJ Max, Walmart, Macy's, Ross Stores and Target.
  • The lowest performers of the specialty retail store brands included Fabletics, Pacsun, Big 5 Sports, and Club Monaco.

Hashflow Unveils Arbitrum-Native Aggregator, Bringing Intent-Based Trading to Arbitrum

Retrieved on: 
Wednesday, March 6, 2024
Ethereum, EVM, Love, HFT, ARB, GMX, MAGIC, News, Risk, Lighter, CMSO, RFQ, DEX, BNB, Ecosystem, Camelot, Cryptocurrency

MIAMI, March 6, 2024 /PRNewswire/ -- Hashflow, a leading decentralized finance (DeFi) trading platform, today announced the launch of its Arbitrum-native aggregator, creating a hub for all Arbitrum ecosystem traders. Through its intent-based, Smart Order Routing architecture, Hashflow's new product, Aggregator+, enables traders to tap into roughly $8B of liquidity to get the best prices on the most popular tokens on Arbitrum. As the Arbitrum DeFi community continues to expand rapidly, Hashflow is positioning itself as a one-stop trading platform for all users in the ecosystem. Hashflow's governance token (HFT) token will also expand onto Arbitrum, in addition to Ethereum and BNB Chain.

Key Points: 
  • As the Arbitrum DeFi community continues to expand rapidly, Hashflow is positioning itself as a one-stop trading platform for all users in the ecosystem.
  • DEX volume continues to surge on Arbitrum, and Hashflow stands to become a central trading hub for all levels of traders in the network."
  • By launching on Arbitrum, Hashflow creates new opportunities for traders to access a broader range of assets and liquidity sources.
  • Hashflow continues to demonstrate its commitment to providing users with seamless and efficient trading experiences across various chains.

Who Owns Delicious? Market Force Releases New Interactive Panel Study That Ranks the Brand Image of Americas Top Fast-Food Restaurants

Retrieved on: 
Monday, August 28, 2023
Market Forces, Growth, CLI, Culver's, QSC, QSR, CMSO, Chick-fil-A, Quality, Retail

Market Force surveyed 3,780 North American consumers about their most recent dining experience to understand which brands are consumer favorites and why.

Key Points: 
  • Market Force surveyed 3,780 North American consumers about their most recent dining experience to understand which brands are consumer favorites and why.
  • The full study ranks 86 brands on factors covering the entire customer journey including QSC (Quality, Service, Cleanliness); speed of service; brand sentiment; menu appeal; loyalty and value measures.
  • The study also explores how controversial statements and actions can polarize consumer opinions about brands.
  • The full study includes a wide array of rankings and charts to showcase who's winning-over the lion's share of consumers.

Who Sets the Bar? Market Force Measures Wireless Carriers in 2023

Retrieved on: 
Wednesday, March 22, 2023
AT&T, Consumer Cellular, Metro, AT, Mint, Network operating system, Tax, Market Forces, IOS, Google Fi, Consumer choice, Xfinity, Android, Acquisition, Straight Talk, Risk, Mobile, Verizon Communications, CLI, Cricket, T-Mobile, CMSO, Spectrum, Spectrum (brand), T-Mobile US, Mobile phone, TracFone Wireless, Mint Mobile

Market Force Information surveyed over 1,500 wireless subscribers across the nation to rate their most recent wireless service experience on a variety of factors.

Key Points: 
  • Market Force Information surveyed over 1,500 wireless subscribers across the nation to rate their most recent wireless service experience on a variety of factors.
  • T-Mobile and Mint Mobile win consumer favor for wireless service and cellular phone plans in Market Force's new study.
  • The big three carriers, Verizon, AT&T and T-Mobile, saw reported market share declines from 75% collectively in 2018 to 70% in 2022.
  • Of the three major carriers, T-Mobile fared the best, increasing market share by close to 9% while the other two carriers lost ground.

Jersey Mike's Tops Competition for Sandwich Quick Serve Restaurant in Market Force Information's 2022 Study

Retrieved on: 
Thursday, March 2, 2023
Popeyes, Arby's, Market Forces, KFC, Church's, McAlister's Deli, Macdonald, Taco Bell, Sonic Drive-In, Box, McDonald's, Noma (restaurant), Cava, Krispy Kreme, Checkers and Rally's, Panera Bread, Firehouse Subs, Little Caesars, Noodles & Company, CMSO, Burger King, McAlister, Raising Cane's Chicken Fingers, Perception, Pizza Hut, Dutch Bros. Coffee, Starbucks, Dairy Queen, Wendy's, Growth, Fire station, El Pollo Loco, Qdoba, Food quality, Panda Express, QSR, CLI, Fast food, Film industry, Retail, Chick-fil-A, Chipotle, Subway, Checkers, Jersey Mike's Subs

ATLANTA, March 2, 2023 /PRNewswire-PRWeb/ -- Jersey Mike's wins customer loyalty and satisfaction in the sandwich category, according to Market Force Information's recent study.

Key Points: 
  • Jersey Mike's wins for best sandwich experience in a Quick Serve Restaurant (QSR), according to Market Force Information's new 2022 QSR / Fast Casual Study.
  • ATLANTA, March 2, 2023 /PRNewswire-PRWeb/ -- Jersey Mike's wins customer loyalty and satisfaction in the sandwich category, according to Market Force Information's recent study.
  • "The customers have spoken," says Scott Griffith, CMSO for Market Force.
  • Over 5,000 people were surveyed in Market Force's 2022 Quick Serve Restaurant (QSR) / Fast Casual Study.

LinKinVax Welcomes Interim Results of the ANRS VRI06 Phase I Trial Evaluating a Novel HIV Vaccine Candidate

Retrieved on: 
Wednesday, February 22, 2023
AIDS, Health, Infectious Diseases, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Safety, HIV, Antibody, Volunteering, CD40, ANRS, Week, Immune system, Risk, Research, VRI, INSERM, Vaccination, RV144, Male, Env, B cell, CMSO, HIV/AIDS, Education, Phase, Pharmaceutical industry, Vaccine

LinKinVax, a clinical-stage biotechnology company, welcomes the interim results of the ANRS VRI06 Phase I trial evaluating a preventive HIV vaccine and conducted by the sponsor INSERM-ANRS and the Vaccine Research Institute (ANRS and Université Paris-Est Créteil, France).

Key Points: 
  • LinKinVax, a clinical-stage biotechnology company, welcomes the interim results of the ANRS VRI06 Phase I trial evaluating a preventive HIV vaccine and conducted by the sponsor INSERM-ANRS and the Vaccine Research Institute (ANRS and Université Paris-Est Créteil, France).
  • These results show that the vaccine candidate is safe and induces an early, significant and sustained immune response.
  • The CD40.HIVRI.Env vaccine candidate is developed by the VRI with a technology whose exclusive worldwide license is held by LinKinVax.
  • This important milestone paves the way for the upcoming Phase II/III clinical studies that we will conduct once the final Phase I results have been obtained.

EQS-News: invIOs to present at Biotech Showcase

Retrieved on: 
Sunday, December 18, 2022
Conference, Immunotherapy, Gesellschaft mit beschränkter Haftung, Biotechnology, CMSO, Epic, Cancer, TILS, Gene expression, IO, Glioblastoma, Patient, Pharmaceutical industry, Medical imaging

Vienna, Austria, 14 December 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter Llewellyn-Davies will present a corporate update during the upcoming Biotech Showcase 2023 meeting in January.

Key Points: 
  • Vienna, Austria, 14 December 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter Llewellyn-Davies will present a corporate update during the upcoming Biotech Showcase 2023 meeting in January.
  • Peter and CMSO Dr Romana Gugenberger are available for meetings with potential investors and partners in San Francisco during the Biotech Showcase / JP Morgan Healthcare Conference week.
  • Details of the invIOs presentation at Biotech Showcase are as follows:
    invIOs is a privately held biotech company based in Vienna, Austria, focusing on the discovery and development of innovative cancer immunotherapies.
  • Once clinically validated, this novel concept will allow access to and treatment for indications not previously addressable by immunotherapy.

invIOs to present at Biotech Showcase

Retrieved on: 
Wednesday, December 14, 2022
Conference, Immunotherapy, Gesellschaft mit beschränkter Haftung, Biotechnology, CMSO, Epic, Cancer, TILS, Gene expression, IO, Glioblastoma, Patient, Pharmaceutical industry, Medical imaging

VIENNA, Austria, Dec. 14, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter Llewellyn-Davies will present a corporate update during the upcoming Biotech Showcase 2023 meeting in January.

Key Points: 
  • VIENNA, Austria, Dec. 14, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter Llewellyn-Davies will present a corporate update during the upcoming Biotech Showcase 2023 meeting in January.
  • Peter and CMSO Dr Romana Gugenberger are available for meetings with potential investors and partners in San Francisco during the Biotech Showcase / JP Morgan Healthcare Conference week.
  • Details of the invIOs presentation at Biotech Showcase are as follows:
    invIOs is a privately held biotech company based in Vienna, Austria, focusing on the discovery and development of innovative cancer immunotherapies.
  • Once clinically validated, this novel concept will allow access to and treatment for indications not previously addressable by immunotherapy.

invIOs presents positive patient data from ongoing Phase 1b trial of APN401 cell therapy in advanced solid tumors at SITC 2022

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Thomas Jefferson National Accelerator Facility, IO, Immunity, Escape Room, Convention center, Poster, Medical University of Vienna, Immunotherapy, Cancer, Department, Gesellschaft mit beschränkter Haftung, Serology, MTD, Glioblastoma, Boston Convention and Exhibition Center, TILS, Alveolar soft part sarcoma, Safety, Gene expression, CMSO, Sirna, SITC, Disease, Neoplasm, Clinical trial, Cell, Liver, Biotechnology, Medical school, Patient, Immune system, Peritoneum, Index (publishing), Hematological Cancer Research Investment and Education Act, Society, Transfusion medicine, Vaccine, Pharmaceutical industry, Medical imaging, Epic

Following tumor resection and 11 lines of prior systemic therapy, the patient was enrolled in the ongoing Phase 1b trial presenting with progressive disease.

Key Points: 
  • Following tumor resection and 11 lines of prior systemic therapy, the patient was enrolled in the ongoing Phase 1b trial presenting with progressive disease.
  • Treatment with APN401 was well tolerated and the patient presented with stable disease for 27 weeks, suggesting immunological anti-tumor activity resulting from treatment with APN401.
  • This supports the potency of APN401 and its potential as an effective therapeutic for malignancies, which is being further investigated in the ongoing clinical trial.
  • APN401 is currently being evaluated in a Phase 1b clinical trial in patients with advanced solid tumors.

invIOs to present data from clinical stage Cbl-b program at SITC 2022

Retrieved on: 
Tuesday, October 18, 2022
Gene expression, Immunotherapy, SITC, Poster, Biotechnology, IO, Patient, JITC, Convention center, Boston Convention and Exhibition Center, CMSO, Gesellschaft mit beschränkter Haftung, Society, Thomas Jefferson National Accelerator Facility, Abstract (summary), Epic, 2021 Essex County Council election, Journal, GLOBE, Glioblastoma, TILS, Pharmaceutical industry, Medical imaging, Cancer

The posters will present new data from the ongoing Phase 1b clinical trial of APN401, a candidate treatment from invIOss EPiC cell therapy platform targeting the master checkpoint inhibitor Cbl-b.

Key Points: 
  • The posters will present new data from the ongoing Phase 1b clinical trial of APN401, a candidate treatment from invIOss EPiC cell therapy platform targeting the master checkpoint inhibitor Cbl-b.
  • Dr. Romana Gugenberger, CMSO, and Dr. Alexander Dohnal, Head of R&D, will attend SITC 2022 and are available for meetings during the event.
  • The Poster Hall will be open from 9 a.m. to 9 p.m. on Thursday, November 10, 2022, and from 9 a.m. to 8:30 p.m. on Friday, November 11, 2022.
  • The ePosters will also be available to attendees on the SITC 2022s Virtual ePoster Hall, as well as on the SITC meeting app and the SITC virtual meeting platform.